
News
Innovation Fund
EU drives decarbonisation with €2.4 billion initiative
The Net Zero Technologies call under Innovation Fund 2024 closes on 24 April 2025
DOCTIS has organized a symposium event focused on “Combination therapies in common diseases: clinical and translational challenges”. This event will be held on the 7th of October 2021, free of charge, online and will start at 5 p.m CET, sponsored by IMIDomics.
DOCTIS is the acronym for the EU-funded project entitled “Decision on Combinatorial Therapies in Immune-Mediated diseases using Systems approaches” aimed at improving treatment efficacy in six Immune-Mediated Inflammatory Diseases (IMIDs), encompassing: Crohn’s disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and psoriatic arthritis.
Despite major advances in the molecular and cellular characterization of common diseases, there has been a steady decline of new effective therapies. Also within approved drugs, significant clinical efficacy is only observed in a subset of patients. Combination therapies could be a useful strategy to overcome this major medical problem. This virtual symposium will be a venue to share insights on the clinical and translational challenges of discovering and implementing combination therapies in common diseases.
17:00 – 17:10: Welcome by Sara Marsal, coordinator of the DOCTIS project and Head of Rheumatology Department in Vall d’Hebron Hospital Campus, Barcelona, Spain.
The first block of presentations: Clinical Challenges. Moderated by Sara Marsal.
17:10 – 17:30: ‘Precision Medicine in Advanced Breast Cancer. – Cristina Saura, Head of Breast Cancer Unit, Vall d’Hebron Institute of Oncology, Barcelona, Spain
17:30 – 17:50: ‘Combination strategies in IBD: opportunity or challenge?’ – Bram Verstockt, clinician-scientist at the Gastroenterology-Hepatology Department at the University Hospitals Leuven, Belgium
17:50 – 18:10: ‘Designing Adaptive Clinical Trials for Combination Therapies in Type 1 Diabetes’ – Adrian Mander, Director of Statistics at the Centre for Trials Research in Cardiff University, UK.
18:10 – 18:25: Q&A
The second block of presentations: Translational challenges. Moderated by Antonio Julià, Head of Rheumatology Research Group in Vall d’Hebron Hospital Campus, Barcelona, Spain.
18:30 – 18:50: ‘Combining high-throughput perturbation experiments and mathematical modeling to identify efficacious combinations’ – Julio Saez–Rodriguez, Head of Systems Biomedicine Group, Heidelberg University, Germany.
18:50 – 19:10: ‘Leveraging multi-modal single-cell atlases to predict perturbations’ – Mohammad Lotfollahi, Institute of Computational Biology, Helmholtz Zentrum München, Germany.
19:10 – 19:30: ‘Network-based prediction of drug combinations’ – István Kovács, Head of Kovacs Labs: Complex Systems, Northwestern University, Evanston, USA.
19:30 – 19:45: Q&A
19:45-19:50: Closing by Sara Marsal, coordinator of the DOCTIS project and Head of Rheumatology Department in Vall d’Hebron Hospital Campus, Barcelona
News
Innovation Fund
The Net Zero Technologies call under Innovation Fund 2024 closes on 24 April 2025
Opinion
THIRD COUNTRIES
Paola Votta
Third Countries Knowledge Area Leader
Publication
Innovation Fund Programme
Uncover the key insights of the Innovation Fund programme, to boost the chances of securing funding for your projects
We provide advice to activities that encourage innovation, aimed at promoting the development of new innovative markets from the demand side, through public procurement.
We can help you with cascading funding, an EC mechanism that distributes public funding to help SMEs develop digital innovation.
We guide companies through the implementation of adequate innovation strategies, which allows them to tackle any transformation challenge in a coordinated and effective manner, from an integrated perspective.